Baxter International Inc.
As of Oct 22, 2026, Baxter International is in Stage 3, the topping phase, now in its first week (since Oct 20, 2026). It closed at $25.65, 9.5% below its 52-week high and above its 200-day average, which is rising.
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BAX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BAX among Medical Instruments & Supplies16th of 51 by relative strength
All 51 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | PLSE | Stage 2 · wk 34 | 98 | +1.3% |
| 2 | PDEX | Stage 2 · wk 36 | 97 | −13.3% |
| 3 | HBIO | Stage 2 · wk 11 | 95 | +3.6% |
| 4 | ATRC | Stage 2 · wk 10 | 89 | −1.1% |
| 5 | WST | Stage 2 · wk 24 | 82 | +4.8% |
| 6 | BDX | Stage 2 · wk 11 | 81 | +9.8% |
| 7 | ICUI | Stage 3 · wk 1 | 81 | +3.1% |
| 8 | OSUR | Stage 3 · wk 8 | 75 | −4.8% |
| …16 | BAX | Stage 3 · wk 1 | 64 | +9.2% |
Baxter International: quick answers
What stage is Baxter International in?
As of Oct 22, 2026, Baxter International (BAX) is in Stage 3, the topping phase. It entered Stage 3 on Oct 20, 2026 and is in its first week there. What the four stages mean
Is Baxter International in an uptrend?
Its uptrend has stalled. Baxter International is in Stage 3, the topping phase that follows an advance. It trades 21.0% above its 200-day average, which is rising.
How far is Baxter International from its 52-week high?
Baxter International closed at $25.65 on Oct 22, 2026, 9.5% below its 52-week high of $28.34. Its 52-week low is $15.79.
How has Baxter International performed over the past year?
As of Oct 22, 2026, Baxter International is up 13.0% over the past year and up 31.7% so far in 2026.
Which sector and industry is Baxter International in?
Baxter International is in the Medical Instruments & Supplies industry, part of the Health Care sector.
About this companyHealth Care· Medical Instruments & Supplies
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.